Ocrevus (Roche) is expected to face US biosimilar competition from 2029. Main US patent protection runs to March 2029. Sales CHF 7.01B.
Ocrevus's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Ocrevus is 11% of Roche's 2025 revenue (≈$8.4B of $74.1B). Group sales CHF 61.5B, including Diagnostics.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Ocrevus is highlighted.